Expert Treatment Recommendations on New Clinical Developments in Frontline Follicular Lymphoma

In this series of 1-hour CME-certified live meetings, expert faculty provide guidance on the latest evidence-based approaches for treating newly diagnosed follicular lymphoma. Afterward, use CCO’s online decision support tool for frontline follicular lymphoma and download the associated slideset and Clinical Resources to enhance the information presented at the live meeting.


  • Obtaining an accurate diagnosis and updated clinical prognostic indices in FL
  • Selection of frontline management approaches for newly diagnosed FL
    • Does the patient need treatment?
    • Frontline anti-CD20 monoclonal antibody–based treatment strategies
      • Antibody monotherapy
      • Chemoimmunotherapy
      • Combination immunotherapy
  • Future directions in the first-line treatment of FL


Date / Time
Event Details


Ian W. Flinn, MD, PhD

Director, Lymphoma Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Nathan Fowler, MD

Associate Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

John Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Carla Casulo, MD

Assistant Professor
Department of Medicine, Hematology/Oncology
Wilmot Cancer Institute
University of Rochester
Rochester, New York

Christopher Flowers, MD

Director, Lymphoma Program
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Oncology
Emory University
Atlanta, Georgia

Nadia Khan, MD

Assistant Professor, Medical Oncology
Fox Chase Cancer Center
Temple University
Philadelphia, Pennsylvania

Brian K. Link, MD

Division of Hematology
Department of Internal Medicine
Holden Comprehensive Cancer Center
University of Iowa
Iowa City, Iowa

Sarah Rutherford, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Weill Cornell Medicine
New York, New York

Bijal Shah, MD

Associate Member
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Mitchell Smith, MD

Associate Center Director for Clinical Investigations
, Division of Oncology and Blood Disorders
George Washington University Cancer Center
Washington, DC

Goal Statement
The goal of this activity is to improve participants’ competence in applying the latest practice-changing data in the clinical management of patients with follicular lymphoma.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with follicular lymphoma.

Learning Objectives

  • Apply emerging clinical trial findings when formulating frontline treatment recommendations for patients with follicular lymphoma
  • Integrate patient-related and disease-related characteristics, patient preferences and goals along with the available clinical evidence to individualize frontline therapy for patients with follicular lymphoma
  • Refer appropriate patients with follicular lymphoma to ongoing clinical trials of investigational frontline agents and approaches


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.